2024-06-13 17:28:51 ET
More on Bristol-Myers Squibb Company
- Bristol-Myers Squibb: Move Investing Time Horizon To 2025, At Least
- Bristol-Myers Squibb: Could This Be A Value Trap? (Technical Analysis)
- Bristol-Myers Squibb Company (BMY) Goldman Sachs 45th Annual Global Healthcare Conference
- Bristol Myers Squibb wins antitrust case against insurers regarding generics
- AstraZeneca dominates, Merck’s Keytruda beaten as ASCO 2024 concludes
Read the full article on Seeking Alpha
For further details see:
Bristol Myers gets FDA approval for Autyro for NTRK-positive cancers